Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,700 result(s) found for: placebo. Displaying page 7 of 635.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2008-001518-26 Sponsor Protocol Number: DFI10569 Start Date*: 2009-03-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Efficacy and safety of oral ataciguat (HMR1766) 200 mg administered once daily for 28 days on pain reduction in patients with Neuropathic Pain. A randomized, double-blind, placebo-controlled, cross...
    Medical condition: The proposed study is planned to demonstrate that ataciguat 200 mg/day could be effective in reducing neuropathic pain with a good safety profile
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005052-40 Sponsor Protocol Number: D1448C00004 Start Date*: 2006-02-24
    Sponsor Name:AstraZeneca AB
    Full Title: “Ensayo multicéntrico, de fase III, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo y con un fármaco activo, de eficacia y seguridad del fumarato de quetiapina de liberación...
    Medical condition: Trastorno depresivo mayor (TDM).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2009-015066-61 Sponsor Protocol Number: ACT10776 Start Date*: 2009-12-11
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.
    Medical condition: Diabetic peripheral neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-003405-94 Sponsor Protocol Number: ABY-035-202 Start Date*: 2020-05-05
    Sponsor Name:ACELYRIN, Inc.
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics a...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005790-60 Sponsor Protocol Number: CL-SBP-101-04 Start Date*: 2022-08-05
    Sponsor Name:Panbela Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Temporarily Halted) IT (Prematurely Ended) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000566-38 Sponsor Protocol Number: R2810-ONC-1788 Start Date*: 2019-10-04
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA
    Medical condition: Patients with features associated with high-risk of recurrent CSCC disease, who have completed surgery and post-operative RT radiation therapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002469-37 Sponsor Protocol Number: CA209-7FL Start Date*: 2020-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi...
    Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-005573-23 Sponsor Protocol Number: 2914-015 Start Date*: 2012-02-20
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: A prospective, randomized, double-blind parallel-arm, placebo-controlled study to assess the effects on ovarian activity of a combined oral contraceptive pill when preceded by the intake of ellaOne...
    Medical condition: Contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011044-20 Sponsor Protocol Number: D1710C00006 Start Date*: 2009-04-08
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, C...
    Medical condition: rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017622-39 Sponsor Protocol Number: ERNLPT01 Start Date*: 2010-04-21
    Sponsor Name:Clinical Center Ljubljana
    Full Title: A double blind, randomized study to compare influence of niacin/laropiprant on functional and morphological characteristics of arterial wall and parameters of inflammation in subjects with CHD alre...
    Medical condition: To evaluate the influence of 12 weeks of ER niacin/laropiprant therapy on endothelial dependent dilatation of the arterial wall in CHD patients already treated with a statin compared to placebo as...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001619-19 Sponsor Protocol Number: TRIO-2016 Start Date*: 2017-03-27
    Sponsor Name:UMC Utrecht
    Full Title: Genistein as an add-on treatment for CF?
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000693-57 Sponsor Protocol Number: Ledin03 Start Date*: 2011-11-29
    Sponsor Name:Håkan Ledin (investigator initiated trial)
    Full Title: A Randomized, Placebo-controlled, Double-blind, Two-center Study with Denosumab in Subjects Undergoing Elective Total Knee Replacement Surgery
    Medical condition: Patients with idiopathic osteoarthritis of the knee, scheduled for a cemented total knee prosthesis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000684-10 Sponsor Protocol Number: ME3301-12 Start Date*: 2004-10-28
    Sponsor Name:Meiji Seika Kaisha, Ltd.
    Full Title: A randomised, double-blind, placebo-controlled crossover study to investigate the efficacy and safety of three doses of ME3301 in patients with seasonal allergic rhinitis during allergen challenge ...
    Medical condition: seasonal allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008594-58 Sponsor Protocol Number: GASAS-0809X Start Date*: 2009-07-24
    Sponsor Name:GABA International AG
    Full Title: In situ mineral change and fluoride retention of sound and demineralized enamel in high cariogenic milieus following the single application of a 1.25%- fluoride or a placebo gel.
    Medical condition: Remineralization, fluoride uptake, and lesion depth of sound and demineralized, plaque-covered enamel after the application of elmex gel will be tested in situ in comparison to a placebo gel.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003362-27 Sponsor Protocol Number: WO17.123 Start Date*: 2018-03-02
    Sponsor Name:OLVG
    Full Title: Ketanserin effects on Peripheral Temperature and Lactate
    Medical condition: Critical illness Delta temperature greater than 6.0 °C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003438-17 Sponsor Protocol Number: 05/Q1606/143 Start Date*: 2005-11-07
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: SimSepT: Simvastatin and severe sepsis in the ICU
    Medical condition: Severe sepsis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005437-11 Sponsor Protocol Number: 06-API-07 Start Date*: 2009-10-05
    Sponsor Name:CHU de NICE
    Full Title: Arthrose érosive des doigts : traitement par méthotrexate versus placebo- évaluation de l’action clinique et structurale (IRM dédiée)- Etude ADEM
    Medical condition: ARTHROSE DIGITALE
    Disease: Version SOC Term Classification Code Term Level
    12.0 10031199 Osteoarthrosis, localized, primary, involving hand LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004836-31 Sponsor Protocol Number: Tav01-13 Start Date*: 2014-04-07
    Sponsor Name:Montavit Ges.m.b.H.
    Full Title: Double-blind, randomised, placebo-controlled study evaluating the efficacy and safety of Tavipec capsules in acute Bronchitis A prsopective, multi-centre, parallel group, interventional clinical ph...
    Medical condition: acute bronchitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-006120-20 Sponsor Protocol Number: 31-06-2011 Start Date*: 2012-03-15
    Sponsor Name:University Medical Centre Ljubljana
    Full Title: Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial
    Medical condition: Proteinuria in kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000007-39 Sponsor Protocol Number: N/A. Start Date*: 2023-03-23
    Sponsor Name:Aarhus University Hospital, Department of Endocrinology and Internal Medicine
    Full Title: Bisphosphonate vs. Placebo Prior to Parathyroidectomy in Primary Hyperparathyroidisme: A Randomized, blinded Placebo-controlled Trial
    Medical condition: Osteopenia i.e. bone mineral density T-score < -1 in patients with primary hyperparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10005991 Bone mass decreased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 11:30:38 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA